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antimicrobial-susceptible and -resistant pathogens were obtained
from the literature or estimated. Resistance and co-resistance
prevalence to ﬁrst- and second-line therapy for the major CAP
pathogens were also derived from local surveillance studies.
Resource use was obtained from Canadian published sources.
Total costs were estimated using standard Ontario sources and a
third-party payer perspective. Outcome measures included ﬁrst-
line clinical failure, second-line treatment and hospitalizations
avoided. RESULTS: The base case incremental cost-effectiveness
ratios (ICERs) comparing moxiﬂoxacin/azithromycin with
azithromycin/moxiﬂoxacin were CDN$96.04 per clinical failure
avoided, CDN$118.71 per second-line treatment avoided, and
CDN$502.47 per hospitalization avoided. One-way sensitivity
analyses demonstrated that the model is robust to change.
The probabilistic sensitivity analysis reported a mean ICER of
CDN$133 (Sd601.47) per clinical failure avoided and a 22%
probability of a moxiﬂoxacin/azithromycin strategy being
cost-saving compared to azithromycin/moxiﬂoxacin. CONCLU-
SION: Antimicrobial failure signiﬁcantly affected outcomes and
costs in empirical outpatient CAP treatment. Despite the higher
costs of proprietary antimicrobial treatments in Canada com-
pared to generic treatments, ﬁrst-line treatment with a ﬂuoroqui-
nolone effective against the major CAP pathogens, including
strains resistant to other antimicrobials, produces signiﬁcantly
better clinical outcomes and relatively low total treatment costs
compared to generic drugs.
PRS10
ECONOMIC AND CLINICAL OUTCOMES OF OMALIZUMAB
USE FORTREATING ASTHMA IN A MANAGED CARE
POPULATION
Prescott J
The MCM Group, Marlton, NJ, USA
OBJECTIVE: The objectives of this analysis were to: 1)Identify a
population of asthma patients new to treatment with omali-
zumab; 2)measure asthma-speciﬁc treatment costs and utilization
for patients initiating treatment with omalizumab; and compare
and quantify, on an annual basis, differences in economics and
other measurable outcomes following initiation of treatment
with omalizumab. METHODS: Using integrated medical and
pharmacy claims data (obtained from the IMS/Pharmetrics
Patient-centric Database), patients were included in the analysis
based on the presence of a diagnosis of asthma (ICD-9 code
493.*) during calendar years 2004 through 2005. Additional
requirements included incident (new) use of omalizumab in
2004. Clinical and economic information related to the treat-
ment of asthma were captured using Episode Treatment Group
(ETG) episode-building software. RESULTS: In 2004, 542
patients (representing 0.1% of the overall asthma population)
were identiﬁed as being newly treated with omalizumab. Within
this group, 66% were diagnosed with extrinsic asthma and 78%
with rhinitis. Total annual costs related to the care of asthma for
this group was $16,643 with $5,926 in medical expenditures.
Following these patients into the next calendar year (2005),
pharmacy costs increased by 33% but medical costs decreased by
42% (to $3411), driven primarily by lower inpatient utilization,
admission rates (from 6.1% to 3.8%), and emergency room
utilization. Additionally, there was decreased use of oral corti-
costeroids and overall use of asthma controllers. CONCLU-
SION: Treatment with omalizumab represents a signiﬁcant
pharmacy investment, and measurable beneﬁts were observed
with respect to medical expenditures and asthma-speciﬁc out-
comes. However, these observations are limited to a very speciﬁc
patient population and further study may be necessary to deter-
mine applicability to other patient groups.
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OBJECTIVE: To compare cost-effectiveness (CE) and cost-utility
(CU) for varenicline vs. other interventions used for smoking
cessation in Czech Republic. METHODS: The Beneﬁt of
Smoking Cessation on Outcomes (BENESCO) Markov simula-
tion model was employed to compare different approaches. The
model simulates morbidity and mortality for the Czech popula-
tion of smokers. In our model a 20-years time horizon was used
to calculate costs and beneﬁts from the payer’s perspective under
current conditions (smoking cessation interventions are not reim-
bursed). Five co-morbidities were considered: chronic obstructive
pulmonary disease, coronary heart disease, stroke, lung cancer
and asthma exacerbations. Calculations were performed in 2007
costs and prices, assuming that 25% of smokers in each age
group make one attempt to quit smoking. Abstinence rates were
extrapolated from literature sources. Local costs and data were
obtained either from literature or expert panels. Assessed inter-
ventions included varenicline, bupropion, nicotine replacement
therapy (NRT) and unaided cessation. RESULTS: Varenicline
dominated all other interventions both in QALY and LYG, and
was cost-saving over the assessed period of 20 years. Beneﬁt of
varenicline was most signiﬁcant in comparison with unaided
cessation (QALY gained 18,186, LYG 12,243, deaths avoided
2004, costs saved €35.5 million—data for all smokers exposed to
intervention). Varenicline was also dominant in comparison to
the most frequently used approach—NRT (QALY gained 7358,
LYG 4953, deaths avoided 811, costs saved €13 million). Bupro-
pion showed similar results to NRT. Varenicline dominated all
other interventions already after ﬁve years. CONCLUSION:
Varenicline is the most effective and cost-effective smoking ces-
sation intervention in Czech Republic from the health care
payer’s perspective. As the prevalence of smokers is high; health
care providers should consider smoking cessation support,
including reimbursement strategies. Further scenarios to conﬁrm
CE and CU also under these conditions are needed.
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OBJECTIVE: To assess the incremental cost-effectiveness of
combining tiotropium (TIO) with salmeterol (SAL) or
salmeterol-ﬂuticasone (SFC) in moderate to severe COPD com-
pared with TIO alone. METHODS: A Markov model was con-
structed to estimate the incremental quality-adjusted life-years
(QALYs) of the three treatment arms. Efﬁcacy data were
obtained from a recently published large randomized controlled
study (Canadian Optimal Therapy of COPD trial). Cost data
were obtained from publicly available data. The cycle length for
the model was set to 3 months and the maximum time horizon
was set to 3 years. The cost-effective analysis was conducted
from a third-party payer’s perspective in the US health care
system. Future costs and effects were discounted at 3%. All costs
are reported in 2007 dollars. Multiple one-way sensitivity analy-
ses and a Monte Carlo simulation were performed to handle
uncertainty. RESULTS: Incremental cost-effectiveness ratios
compared with TIO alone were $152,743/QALY in the
TIO + SAL group, and $51,610/QALY in the TIO + SFC group.
An acceptability curve revealed TIO + SAL was more cost-
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